Broad Enough? Sponsors Pleased With Narrower Praluent Label
This article was originally published in The Pink Sheet Daily
Indication for cholesterol-lowering drug is narrower than Sanofi and Regeneron originally sought, but firms still see it as broad. Target patient population is estimated at 8-10 million patients, but sponsors are quick to say the number of actual users will be funneled down.
Register for our free email digests: